110 related articles for article (PubMed ID: 20089977)
1. Clostridium difficile--beyond antibiotics.
Kyne L
N Engl J Med; 2010 Jan; 362(3):264-5. PubMed ID: 20089977
[No Abstract] [Full Text] [Related]
2. Treatment with monoclonal antibodies against Clostridium difficile toxins.
Lowy I; Molrine DC; Leav BA; Blair BM; Baxter R; Gerding DN; Nichol G; Thomas WD; Leney M; Sloan S; Hay CA; Ambrosino DM
N Engl J Med; 2010 Jan; 362(3):197-205. PubMed ID: 20089970
[TBL] [Abstract][Full Text] [Related]
3. Treatment with monoclonal antibodies against Clostridium difficile toxins.
Safdar A
N Engl J Med; 2010 Apr; 362(15):1444-5; author reply 1445-6. PubMed ID: 20397289
[No Abstract] [Full Text] [Related]
4. Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI).
Leav BA; Blair B; Leney M; Knauber M; Reilly C; Lowy I; Gerding DN; Kelly CP; Katchar K; Baxter R; Ambrosino D; Molrine D
Vaccine; 2010 Jan; 28(4):965-9. PubMed ID: 19941990
[TBL] [Abstract][Full Text] [Related]
5. Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters.
Babcock GJ; Broering TJ; Hernandez HJ; Mandell RB; Donahue K; Boatright N; Stack AM; Lowy I; Graziano R; Molrine D; Ambrosino DM; Thomas WD
Infect Immun; 2006 Nov; 74(11):6339-47. PubMed ID: 16966409
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of protection against Clostridium difficile infection by the monoclonal antitoxin antibodies actoxumab and bezlotoxumab.
Yang Z; Ramsey J; Hamza T; Zhang Y; Li S; Yfantis HG; Lee D; Hernandez LD; Seghezzi W; Furneisen JM; Davis NM; Therien AG; Feng H
Infect Immun; 2015 Feb; 83(2):822-31. PubMed ID: 25486992
[TBL] [Abstract][Full Text] [Related]
7. Fecal microbiota transplantation and emerging treatments for Clostridium difficile infection.
Gens KD; Elshaboury RH; Holt JS
J Pharm Pract; 2013 Oct; 26(5):498-505. PubMed ID: 23966282
[TBL] [Abstract][Full Text] [Related]
8. A Combination of Three Fully Human Toxin A- and Toxin B-Specific Monoclonal Antibodies Protects against Challenge with Highly Virulent Epidemic Strains of Clostridium difficile in the Hamster Model.
Anosova NG; Cole LE; Li L; Zhang J; Brown AM; Mundle S; Zhang J; Ray S; Ma F; Garrone P; Bertraminelli N; Kleanthous H; Anderson SF
Clin Vaccine Immunol; 2015 Jul; 22(7):711-25. PubMed ID: 25924765
[TBL] [Abstract][Full Text] [Related]
9. Treatment with monoclonal antibodies against Clostridium difficile toxins.
Dawson AE; Shumak SL; Redelmeier DA
N Engl J Med; 2010 Apr; 362(15):1445; author reply 1445-6. PubMed ID: 20397290
[No Abstract] [Full Text] [Related]
10. Disease Progression and Resolution in Rodent Models of Clostridium difficile Infection and Impact of Antitoxin Antibodies and Vancomycin.
Warn P; Thommes P; Sattar A; Corbett D; Flattery A; Zhang Z; Black T; Hernandez LD; Therien AG
Antimicrob Agents Chemother; 2016 Nov; 60(11):6471-6482. PubMed ID: 27527088
[TBL] [Abstract][Full Text] [Related]
11. Clostridium difficile antibodies: a patent evaluation (WO2013028810).
Lo Vecchio A; Della Ventura B; Nicastro E
Expert Opin Ther Pat; 2013 Dec; 23(12):1635-40. PubMed ID: 23978053
[TBL] [Abstract][Full Text] [Related]
12. Actoxumab + bezlotoxumab combination: what promise for Clostridium difficile treatment?
Posteraro B; Pea F; Masucci L; Posteraro P; Sanguinetti M
Expert Opin Biol Ther; 2018 Apr; 18(4):469-476. PubMed ID: 29534621
[TBL] [Abstract][Full Text] [Related]
13. A mixture of functionally oligoclonal humanized monoclonal antibodies that neutralize Clostridium difficile TcdA and TcdB with high levels of in vitro potency shows in vivo protection in a hamster infection model.
Davies NL; Compson JE; Mackenzie B; O'Dowd VL; Oxbrow AK; Heads JT; Turner A; Sarkar K; Dugdale SL; Jairaj M; Christodoulou L; Knight DE; Cross AS; Hervé KJ; Tyson KL; Hailu H; Doyle CB; Ellis M; Kriek M; Cox M; Page MJ; Moore AR; Lightwood DJ; Humphreys DP
Clin Vaccine Immunol; 2013 Mar; 20(3):377-90. PubMed ID: 23324518
[TBL] [Abstract][Full Text] [Related]
14. Systemically administered IgG anti-toxin antibodies protect the colonic mucosa during infection with Clostridium difficile in the piglet model.
Cohen OR; Steele JA; Zhang Q; Schmidt DJ; Wang Y; Hamel PE; Beamer G; Xu B; Tzipori S
PLoS One; 2014; 9(10):e111075. PubMed ID: 25347821
[TBL] [Abstract][Full Text] [Related]
15. Discrepancies in testing recommendations for Clostridium difficile infection: updated review favors amplification test systems.
Chapin K
Expert Rev Mol Diagn; 2012 Apr; 12(3):223-6. PubMed ID: 22468811
[No Abstract] [Full Text] [Related]
16. Clostridium difficile lacks detectable superantigen activity.
Wanahita A; Davis B; Hamill RJ; Goldsmith EA; Rodgers JR; Cook RG; Lamphear JG; Musher DM
FEMS Immunol Med Microbiol; 2006 Jul; 47(2):275-7. PubMed ID: 16831215
[TBL] [Abstract][Full Text] [Related]
17. Recurrent Clostridium difficile infection: an immunodeficiency state?
Pardi DS
Clin Gastroenterol Hepatol; 2007 Jun; 5(6):672-3. PubMed ID: 17544993
[No Abstract] [Full Text] [Related]
18. A Tetraspecific VHH-Based Neutralizing Antibody Modifies Disease Outcome in Three Animal Models of Clostridium difficile Infection.
Schmidt DJ; Beamer G; Tremblay JM; Steele JA; Kim HB; Wang Y; Debatis M; Sun X; Kashentseva EA; Dmitriev IP; Curiel DT; Shoemaker CB; Tzipori S
Clin Vaccine Immunol; 2016 Sep; 23(9):774-84. PubMed ID: 27413067
[TBL] [Abstract][Full Text] [Related]
19. Clostridial toxins: sensing a target in a hostile gut environment.
Oezguen N; Power TD; Urvil P; Feng H; Pothoulakis C; Stamler JS; Braun W; Savidge TC
Gut Microbes; 2012; 3(1):35-41. PubMed ID: 22356854
[TBL] [Abstract][Full Text] [Related]
20. The safety of whey protein concentrate derived from the milk of cows immunized against Clostridium difficile.
Young KW; Munro IC; Taylor SL; Veldkamp P; van Dissel JT
Regul Toxicol Pharmacol; 2007 Apr; 47(3):317-26. PubMed ID: 17293018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
